ISDA: 5WAL

Deposition Date 2017-06-26

Release Date 2017-09-06

Last Version Date 2023-10-04

Entry Detail

PDB ID:

5WAL

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

unidentified baculovirus

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.45 Å

R-Value Free:

0.24

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Non-receptor tyrosine-protein kinase TYK2
Gene (Uniprot):TYK2
Mutagens:C936A, Q969A, E971A, K972A, S1016A, C1142A, D1023N
Chain IDs:A
Chain Length:302
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P29597 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

9ZS

Primary Citation

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.

Liang, J, Van Abbema, A, Balazs, M, Barrett, K, Berezhkovsky, L, Blair, W.S, Chang, C, Delarosa, D, DeVoss, J, Driscoll, J, Eigenbrot, C, Goodacre, S, Ghilardi, N, MacLeod, C, Johnson, A, Bir Kohli, P, Lai, Y, Lin, Z, Mantik, P, Menghrajani, K, Nguyen, H, Peng, I, Sambrone, A, Shia, S, Smith, J, Sohn, S, Tsui, V, Ultsch, M, Williams, K, Wu, L.C, Yang, W, Zhang, B, Magnuson, S.Show

Bioorg. Med. Chem. Lett. 27 4370 4376 (2017)

PMID: 28830649 DOI: 10.1016/j.bmcl.2017.08.022

Abstact

Herein we report identification of an imidazopyridine class of potent and selective TYK2 inhibitors, exemplified by prototype 6, through constraint of the rotatable amide bond connecting the pyridine and aryl rings of compound 1. Further optimization led to generation of compound 30 that potently inhibits the TYK2 enzyme and the IL-23 pathway in cells, exhibits selectivity against cellular JAK2 activity, and has good pharmacokinetic properties. In mice, compound 30 demonstrated dose-dependent reduction of IL-17 production in a PK/PD model as well as in an imiquimod-induced psoriasis model. In this efficacy model, the IL-17 decrease was accompanied by a reduction of ear thickness indicating the potential of TYK2 inhibition as a therapeutic approach for psoriasis patients.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form